• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Case Report of Acute Intracerebral Vascular Ischemic Stroke After Treatment with Dihydroergotamine in a * Patient with New Onset of Migraine New Daily Persistant Headache with Thunderclap Onset (S41.008)
CONCLUSIONS: We report this case of a Stroke occuring in a patient who failed conventional outpatient management of sudden onset migraine-like headache that we suspect may have been on the spectrum of RCVS. Prior to this no reports have been published on a stroke possibly being a side effect or complication of DHE therapy. One prior report has suggested DHE caused RCVS in a migraine patient on citalopram, supporting the concept that DHE should be avoided in the setting of recent onset RCVS.Disclosure: Dr. Ghafoor has nothing to disclose. Dr. Young has received personal compensation for activities with Merck & Co. Inc. ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ghafoor, S., Young, W. Tags: Headache: Clinical Source Type: research

A Case Report of Dihydroergotamine Administration for Status Migrainosus in a Patient on Longstanding Citalopram Causing a Fatal Reversible Cerebral Vasoconstriction Syndrome (RCVS) (P02.027)
CONCLUSIONS: We report this case report of fatal RCVS of a patient on long standing citalopram who developed this after being administered Dihydroergotamine for status migrainosus. As this is thought to be a self-limiting in terms of clinical features. However, some patients may have more severe focal neurologic symptoms and signs, including ischemic or hemorrhagic strokes as described in our patient.Disclosure: Dr. Asi has nothing to disclose. Dr. Gomes has nothing to disclose. Dr. Dani has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Asi, K., Gomes, J., Dani, D. Tags: P02 Cerebrovascular Disease II Source Type: research